TY - JOUR
T1 - Pre-diagnostic circulating insulin-like growth factor-I and bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition
AU - Lin, Crystal
AU - Travis, Ruth C.
AU - Appleby, Paul N.
AU - Tipper, Sarah
AU - Weiderpass, Elisabete
AU - Chang-Claude, Jenny
AU - Gram, Inger T.
AU - Kaaks, Rudolf
AU - Kiemeney, Lambertus A.
AU - Ljungberg, Börje
AU - Tumino, Rosario
AU - Tjønneland, Anne
AU - Roswall, Nina
AU - Overvad, Kim
AU - Boutron-Ruault, Marie Christine
AU - Manciniveri, Francesca Romana
AU - Severi, Gianluca
AU - Trichopoulou, Antonia
AU - Masala, Giovanna
AU - Sacerdote, Carlotta
AU - Agnoli, Claudia
AU - Panico, Salvatore
AU - Bueno-de-Mesquita, Bas
AU - Peeters, Petra H.
AU - Salamanca-Fernández, Elena
AU - Chirlaque, Maria Dolores
AU - Ardanaz, Eva
AU - Dorronsoro, Miren
AU - Menéndez, Virginia
AU - Luján-Barroso, Leila
AU - Liedberg, Fredrik
AU - Freisling, Heinz
AU - Gunter, Marc
AU - Aune, Dagfinn
AU - Cross, Amanda J.
AU - Riboli, Elio
AU - Key, Timothy J.
AU - Perez-Cornago, Aurora
N1 - Funding Information:
Key words: bladder cancer, urothelial cell carcinoma, IGF-I, EPIC cohort, prospective Abbreviations: BMI: body mass index; EPIC: European Prospective Investigation into Cancer and Nutrition; IARC: International Agency for Research on Cancer; IGF-I: insulin-like growth factor I; IGF-IR: insulin-like growth factor I receptor; LRT: likelihood ratio test; OR: odds ratio; UCC: urothelial cell carcinoma; UK: United Kingdom; VEG-F: vascular endothelial growth factor Additional Supporting Information may be found in the online version of this article. For information on how to submit an application for gaining access to EPIC data and/or biospecimens, please follow the instructions at http:// epic.iarc.fr/access/index.php Conflict of interest: The authors declare that they have no conflicts of interest. Grant sponsor: Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy; Grant sponsor: Cancer Research UK; Grant numbers: 14136C570/A11692, C570/A16491, C8221/A19170; Grant sponsor: Catalan Institute of Oncology; Grant sponsor: County Councils of Skåne and Västerbotten; Grant sponsor: Danish Cancer Society; Grant sponsor: Deutsche Krebshilfe; Grant sponsor: Deutsches Krebsforschungszentrum; Grant sponsor: Dutch Ministry of Public Health; Grant sponsor: Dutch Prevention Funds; Grant sponsor: Dutch ZON (Zorg Onderzoek Nederland); Grant sponsor: ERC-2009; Grant numbers: AdG 232997; Grant sponsor: European Commission (DG-SANCO); Grant sponsor: FEDER funds/European Regional Development Fund (ERDF) “A Way to Build Europe”; Grant sponsor: Federal Ministry of Education and Research (BMBF); Grant sponsor: German Cancer Aid; Grant sponsor: German Cancer Research Center (DKFZ); Grant sponsor: Health Research Fund (FIS); Grant numbers: PI13/00061, PI13/01162; Grant sponsor: Institut Gustave Roussy; Grant sponsor: Institut National de la Santé et de la Recherche Médicale (INSERM); Grant sponsor: International Agency for Research on Cancer (IARC); Grant sponsor: ISCIII RETIC; Grant numbers: RD06/0020; Grant sponsor: Ligue Contre le Cancer; Grant sponsor: LK Research Funds; Grant sponsor: Medical Research Council; Grant numbers: 1000143MR/M012190/1; Grant sponsor: Mutuelle Générale de l’Education Nationale; Grant sponsor: National Research Council-Italy; Grant sponsor: Netherlands Cancer Registry (NKR); Grant sponsor: Red Tematica de Investigacion Cooperativa en Cancer of the Instituto de Salud Carlos III; Grant numbers: ISCIII RTICC RD12/0036/0018; Grant sponsor: Spanish Regional Governments; Grant sponsor: Statistics Netherlands; Grant sponsor: Swedish Cancer Society; Grant sponsor: Swedish Research Council; Grant sponsor: The Hellenic Health Foundation; Grant sponsor: Welfare and Sports (VWS); Grant sponsor: World Cancer Research Fund (WCRF) DOI: 10.1002/ijc.31650 This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. History: Received 22 Jan 2018; Accepted 2 May 2018; Online 4 July 2018 Correspondence to: Dr Aurora Perez-Cornago, Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford, OX3 7LF, UK, E-mail: [email protected], Tel: +44 (0)1865 289600
Publisher Copyright:
© 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
PY - 2018/11/15
Y1 - 2018/11/15
N2 - Previous in vitro and case–control studies have found an association between the insulin-like growth factor (IGF)-axis and bladder cancer risk. Circulating concentrations of IGF-I have also been found to be associated with an increased risk of several cancer types; however, the relationship between pre-diagnostic circulating IGF-I concentrations and bladder cancer has never been studied prospectively. We investigated the association of pre-diagnostic plasma concentrations of IGF-I with risk of overall bladder cancer and urothelial cell carcinoma (UCC) in a case–control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 843 men and women diagnosed with bladder cancer between 1992 and 2005 were matched with 843 controls by recruitment centre, sex, age at recruitment, date of blood collection, duration of follow-up, time of day and fasting status at blood collection using an incidence density sampling protocol. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression with adjustment for smoking status. No association was found between pre-diagnostic circulating IGF-I concentration and overall bladder cancer risk (adjusted OR for highest versus lowest fourth: 0.91, 95% CI: 0.66–1.24, ptrend = 0.40) or UCC (n of cases = 776; 0.91, 0.65–1.26, ptrend = 0.40). There was no significant evidence of heterogeneity in the association of IGF-I with bladder cancer risk by tumour aggressiveness, sex, smoking status, or by time between blood collection and diagnosis (pheterogeneity > 0.05 for all). This first prospective study indicates no evidence of an association between plasma IGF-I concentrations and bladder cancer risk.
AB - Previous in vitro and case–control studies have found an association between the insulin-like growth factor (IGF)-axis and bladder cancer risk. Circulating concentrations of IGF-I have also been found to be associated with an increased risk of several cancer types; however, the relationship between pre-diagnostic circulating IGF-I concentrations and bladder cancer has never been studied prospectively. We investigated the association of pre-diagnostic plasma concentrations of IGF-I with risk of overall bladder cancer and urothelial cell carcinoma (UCC) in a case–control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 843 men and women diagnosed with bladder cancer between 1992 and 2005 were matched with 843 controls by recruitment centre, sex, age at recruitment, date of blood collection, duration of follow-up, time of day and fasting status at blood collection using an incidence density sampling protocol. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression with adjustment for smoking status. No association was found between pre-diagnostic circulating IGF-I concentration and overall bladder cancer risk (adjusted OR for highest versus lowest fourth: 0.91, 95% CI: 0.66–1.24, ptrend = 0.40) or UCC (n of cases = 776; 0.91, 0.65–1.26, ptrend = 0.40). There was no significant evidence of heterogeneity in the association of IGF-I with bladder cancer risk by tumour aggressiveness, sex, smoking status, or by time between blood collection and diagnosis (pheterogeneity > 0.05 for all). This first prospective study indicates no evidence of an association between plasma IGF-I concentrations and bladder cancer risk.
KW - bladder cancer
KW - EPIC cohort
KW - IGF-I
KW - prospective
KW - urothelial cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85053382965&partnerID=8YFLogxK
U2 - 10.1002/ijc.31650
DO - 10.1002/ijc.31650
M3 - Article
AN - SCOPUS:85053382965
SN - 0020-7136
VL - 143
SP - 2351
EP - 2358
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 10
ER -